CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study

P S Burge¹, P M A Calverley², P W Jones³, S Spencer³, J A Anderson⁴ on behalf of the ISOLDE Study Group

¹ Birmingham Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS, UK
² University Hospital Aintree, Liverpool L9 7AL, UK
³ St George’s Hospital Medical School, London SW17 0RE, UK
⁴ GlaxoWellcome Research and Development, Stockley Park West, Middlesex, UK

Correspondence to:
Correspondence to:
Professor P S Burge, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS, UK;
sherwood.burge{at}heartsol.wmids.nhs.uk

Background: A trial of corticosteroids has been recommended for all patients with chronic obstructive pulmonary disease (COPD), with the subsequent "response" determining the treatment selected. This approach assumes that patients can be reliably divided into responder and non-responder groups. We have assessed whether such a separation is statistically valid, which factors influence the change in forced expiratory volume in 1 second (FEV₁) after prednisolone, and whether the prednisolone response predicts 3 year changes in FEV₁, health status, or number of exacerbations during placebo or fluticasone propionate treatment.

Methods: Oral prednisolone 0.6 mg/kg was given for 14 days to 524 patients with COPD before randomised treatment for 3 years with fluticasone propionate or placebo. Factors relating to change in FEV₁ after prednisolone were investigated using multiple regression. The response to prednisolone was entered into separate mixed effects models of decline in FEV₁ and health status during the 3 years of the study.

Results: The post-bronchodilator FEV₁ increased by a mean 60 ml (CI 46 to 74) after prednisolone with a wide unimodal distribution. Current smoking was the factor most strongly associated with the change in FEV₁ after prednisolone, with an increase of 35 ml in current smokers and 74 ml in confirmed ex-smokers (p<0.001). There was no relationship between the change in FEV₁ after prednisolone and the response to inhaled bronchodilators, baseline FEV₁, atopic status, age, or sex. The response to prednisolone, however expressed, was unrelated to the subsequent change in FEV₁ over the following 3 years on either placebo or fluticasone propionate. Regression to the mean effects explained much of the apparent prednisolone response. The significant effect of treatment on decline in health status was not predicted by the prednisolone response.

Conclusion: Patients with COPD cannot be separated into discrete groups of corticosteroid responders and non-responders. Current smoking reduces the FEV₁ response to prednisolone. Prednisolone testing is an unreliable predictor of the benefit from inhaled fluticasone propionate in individual patients.

Keywords: chronic obstructive pulmonary disease; prednisolone

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Airwaves

Wisia Wedzicha
Thorax 2003 58: 647. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Dummer, J. F., Epton, M. J., Cowan, J. O., Cook, J. M., Condliffe, R., Landhuis, C. E., Smith, A. D., Taylor, D. R. (2009). Predicting Corticosteroid Response in Chronic Obstructive Pulmonary Disease Using Exhaled Nitric Oxide. Am. J. Respir. Crit. Care Med. 180: 846-852 [Abstract] [Full Text]  
• Rabe, K. F., Timmer, W., Sagkriotis, A., Viel, K. (2008). Comparison of a Combination of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Moderate COPD. Chest 134: 255-262 [Abstract] [Full Text]  
• Braganza, G., Chaudhuri, R., Thomson, N. C. (2008). Review: Treating patients with respiratory disease who smoke. Ther Adv Respir Dis 2: 95-107 [Abstract]  
• Suissa, S., McGhan, R., Niewoehner, D., Make, B. (2007). Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 4: 535-542 [Abstract] [Full Text]  
• Rabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. A., Calverley, P., Fukuchi, Y., Jenkins, C., Rodriguez-Roisin, R., van Weel, C., Zielinski, J. (2007). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary. Am. J. Respir. Crit. Care Med. 176: 532-555 [Abstract] [Full Text]  
• Roche, N. (2007). Where current pharmacological therapies fall short in COPD: symptom control is not enough. ERR 16: 98-104 [Abstract] [Full Text]  
• Meguro, M., Barley, E. A., Spencer, S., Jones, P. W. (2007). Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire. Chest 132: 456-463 [Abstract] [Full Text]  
• Walker, P. P., Mitchell, P., Diamantea, F., Warburton, C. J., Davies, L. (2006). Effect of primary-care spirometry on the diagnosis and management of COPD. Eur Respir J 28: 945-952 [Abstract] [Full Text]  
• Leclerc, O., Lagente, V., Planquois, J-M., Berthelier, C., Artola, M., Eichholtz, T., Bertrand, C. P., Schmidlin, F. (2006). Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice. Eur Respir J 27: 1102-1109 [Abstract] [Full Text]  
• Leigh, R., Pizzichini, M. M. M., Morris, M. M., Maltais, F., Hargreave, F. E., Pizzichini, E. (2006). Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 27: 964-971 [Abstract] [Full Text]  
• Saha, S., Siva, R., Brightling, C. E., Pavord, I. D. (2006). COPD: an inhaled corticosteroid-resistant, oral corticosteroid-responsive condition.. Eur Respir J 27: 863-865 [Full Text]  
• Sin, D D, Wu, L, Anderson, J A, Anthonisen, N R, Buist, A S, Burge, P S, Calverley, P M, Connett, J E, Lindmark, B, Pauwels, R A, Postma, D S, Soriano, J B, Szafranski, W, Vestbo, J (2005). Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 60: 992-997 [Abstract] [Full Text]  
• Brightling, C E, McKenna, S, Hargadon, B, Birring, S, Green, R, Siva, R, Berry, M, Parker, D, Monteiro, W, Pavord, I D, Bradding, P (2005). Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 60: 193-198 [Abstract] [Full Text]  
• Thomson, N.C., Chaudhuri, R., Livingston, E. (2004). Asthma and cigarette smoking. Eur Respir J 24: 822-833 [Abstract] [Full Text]  
• Donohue, J. F., Ohar, J. A. (2004). Effects of Corticosteroids on Lung Function in Asthma and Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 1: 152-160 [Abstract] [Full Text]  
• Perng, D.-W., Huang, H.-Y., Chen, H.-M., Lee, Y.-C., Perng, R.-P. (2004). Characteristics of Airway Inflammation and Bronchodilator Reversibility in COPD: A Potential Guide to Treatment. Chest 126: 375-381 [Abstract] [Full Text]  
• Hopkinson, N.S., Man, W.D-C., Dayer, M.J., Ross, E.T., Nickol, A.H., Hart, N., Moxham, J., Polkey, M.I. (2004). Acute effect of oral steroids on muscle function in chronic obstructive pulmonary disease. Eur Respir J 24: 137-142 [Abstract] [Full Text]  
• Sutherland, E. R., Cherniack, R. M. (2004). Management of Chronic Obstructive Pulmonary Disease. NEJM 350: 2689-2697 [Full Text]  
• D'Urzo, A. D., Calverley, P. M. A. (2004). Withdrawal of Treatment in the ISOLDE Study. Chest 125: 2368-2368 [Full Text]  
• Calverley, P M A (2004). Breathlessness during exercise in COPD: how do the drugs work?. Thorax 59: 455-457 [Full Text]  
• Molfino, N. A. (2004). Genetics of COPD. Chest 125: 1929-1940 [Abstract] [Full Text]  
• Pavord, I D, Siva, R, Brightling, C E, Burge, P S, Calverley, P M A, Jones, P W, Spencer, S (2004). Prednisolone response in patients with COPD * Authors' reply. Thorax 59: 179-179 [Full Text]  
• Burge, P S, Lewis, S A (2003). So inhaled steroids slow the rate of decline of FEV1 in patients with COPD after all?. Thorax 58: 911-913 [Full Text]  
• Gross, N J (2003). Responses to steroids and bronchodilators in COPD in the ISOLDE trial: the fat lady sings on. Thorax 58: 647-648 [Full Text]